Get started
Veracyte, Inc.Veracyte, Inc.Veracyte, Inc.

Veracyte, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

VCYT chart


Full chart

VCYT upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.46 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
102.87
Basic EPS (TTM)
0.31 USD
Net income (FY)
‪24.14 M‬ USD
Revenue (FY)
‪445.76 M‬ USD
Shares float
‪76.84 M‬
Beta (1Y)
1.47

Employees


Employees (FY)
824
Change (1Y)
+9 +1.10%
Revenue / Employee (1Y)
‪540.98 K‬ USD
Net income / Employee (1Y)
‪29.29 K‬ USD

About Veracyte, Inc.


Sector
Health Technology
Industry
Medical Specialties
CEO
Marc A. Stapley
Website
veracyte.com
Headquarters
South San Francisco
Founded
2006
FIGI
BBG001J2M542
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VCYT news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as VCYT.

Frequently Asked Questions


The current price of VCYT is 31.14 USD — it has decreased by −1.24% in the past 24 hours. Watch Veracyte, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Veracyte, Inc. stocks are traded under the ticker VCYT.
VCYT stock has fallen by −0.096% compared to the previous week, the month change is a 0.61% rise, over the last year Veracyte, Inc. has showed a 62.44% increase.
We've gathered analysts' opinions on Veracyte, Inc. future price: according to them, VCYT price has a max estimate of 54.00 USD and a min estimate of 29.00 USD. Watch VCYT chart and read a more detailed Veracyte, Inc. stock forecast: see what analysts think of Veracyte, Inc. and suggest that you do with its stocks.
VCYT reached its all-time high on Feb 10, 2021 with the price of 86.03 USD, and its all-time low was 4.21 USD and was reached on Mar 24, 2016. View more price dynamics on VCYT chart.
See other stocks reaching their highest and lowest prices.
VCYT stock is 2.47% volatile and has beta coefficient of 1.47. Track Veracyte, Inc. stock price on the chart and check out the list of the most volatile stocks — is Veracyte, Inc. there?
Today Veracyte, Inc. has the market capitalization of ‪2.46 B‬, it has decreased by −2.64% over the last week.
Yes, you can track Veracyte, Inc. financials in yearly and quarterly reports right on TradingView.
Veracyte, Inc. is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
VCYT earnings for the last quarter are 0.06 USD per share, whereas the estimation was 0.11 USD resulting in a −47.06% surprise. The estimated earnings for the next quarter are 0.023 USD per share. See more details about Veracyte, Inc. earnings.
Veracyte, Inc. revenue for the last quarter amounts to ‪118.63 M‬ USD, despite the estimated figure of ‪116.70 M‬ USD. In the next quarter, revenue is expected to reach ‪110.90 M‬ USD.
VCYT net income for the last quarter is ‪5.11 M‬ USD, while the quarter before that showed ‪15.15 M‬ USD of net income which accounts for −66.26% change. Track more Veracyte, Inc. financial stats to get the full picture.
No, VCYT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 18, 2025, the company has 824 employees. See our rating of the largest employees — is Veracyte, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Veracyte, Inc. EBITDA is ‪47.19 M‬ USD, and current EBITDA margin is 12.71%. See more stats in Veracyte, Inc. financial statements.
Like other stocks, VCYT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Veracyte, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Veracyte, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Veracyte, Inc. stock shows the buy signal. See more of Veracyte, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.